Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Immunosuppressive protocols with tacrolimus after cryopreserved aortal allotransplantation in rats

R. Spunda, J. Hruby, P. Mericka, M. Mlcek, O. Pecha, K. Splith, M. Schmelzle, F. Krenzien, J. Lindner, I. Matia, M. Spacek,

. 2018 ; 13 (8) : e0201984. [pub] 20180809

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19012486

OBJECTIVES AND DESIGN: The aim of our study was to simulate in rats all aspects and techniques used in our new clinical program of cryopreserved alloarterial transplantation and investigate the influence of two immunosuppressive protocols with tacrolimus on acute rejection of these allografts. MATERIALS AND METHODS: Cryopreserved abdominal aortic grafts were transplanted between Brown-Norway and Lewis rats. Tacrolimus (0.2 mg/kg daily) was administered from day 1 to day 30 (TAC1) or from day 7 to day 30 (TAC7), respectively. No immunosuppressed isogeneic (ISO) and allogeneic (ALO) rats combination served as control. Aortal wall infiltration by immunocompetent cells (MHC II+ cells of recipient origin) was studied on day 30 after transplantation. Flow cytometry was used for the analysis of day 30 sera for the presence of donor specific anti-MHC class I and II antibodies. RESULTS: The aortal allografts in both immunosuppressed groups showed regular morphology of aortal wall with no depositions of immunoglobulin G on day 30. The adventitial infiltration of non-immunosuppressed aortal allografts by MHC class II positive cells of recipient origin was significantly higher (ALO 20.7±6.7 cells, P<0.001) compared to both immunosuppressed groups (TAC1 5.9±5.5 cells, TAC7 6.1±5.1 cells). Day 30 sera from the allogeneic non-immunosuppressed animals decreased significantly the binding of fluorescence-labelled MHC class I (46.9±19.4%) and class II (65.8±11.9%) antibody to donors spleen cells compared with day 30 sera from both immunosuppressed groups (TAC1, anti-MHC class I 102.4±4.2%, p < 0.001, anti-MHC class II 102.6±6.0%), (TAC7, anti-MHC class I 79.9±3.3%, p < 0.001, anti-MHC class II 80.9±2.7%). CONCLUSION: Both immunosuppressed protocols with tacrolimus (administration from day 1 or from day 7 following transplantation) were able to suppress acute cell- and antibody-mediated rejection of cryopreserved abdominal aortic allografts processed in accordance with our new standardized clinical protocol.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012486
003      
CZ-PrNML
005      
20190405131411.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0201984 $2 doi
035    __
$a (PubMed)30092051
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Spunda, Rudolf $u 2nd Department of Surgery - Department of Cardiovascular Surgery, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
245    10
$a Immunosuppressive protocols with tacrolimus after cryopreserved aortal allotransplantation in rats / $c R. Spunda, J. Hruby, P. Mericka, M. Mlcek, O. Pecha, K. Splith, M. Schmelzle, F. Krenzien, J. Lindner, I. Matia, M. Spacek,
520    9_
$a OBJECTIVES AND DESIGN: The aim of our study was to simulate in rats all aspects and techniques used in our new clinical program of cryopreserved alloarterial transplantation and investigate the influence of two immunosuppressive protocols with tacrolimus on acute rejection of these allografts. MATERIALS AND METHODS: Cryopreserved abdominal aortic grafts were transplanted between Brown-Norway and Lewis rats. Tacrolimus (0.2 mg/kg daily) was administered from day 1 to day 30 (TAC1) or from day 7 to day 30 (TAC7), respectively. No immunosuppressed isogeneic (ISO) and allogeneic (ALO) rats combination served as control. Aortal wall infiltration by immunocompetent cells (MHC II+ cells of recipient origin) was studied on day 30 after transplantation. Flow cytometry was used for the analysis of day 30 sera for the presence of donor specific anti-MHC class I and II antibodies. RESULTS: The aortal allografts in both immunosuppressed groups showed regular morphology of aortal wall with no depositions of immunoglobulin G on day 30. The adventitial infiltration of non-immunosuppressed aortal allografts by MHC class II positive cells of recipient origin was significantly higher (ALO 20.7±6.7 cells, P<0.001) compared to both immunosuppressed groups (TAC1 5.9±5.5 cells, TAC7 6.1±5.1 cells). Day 30 sera from the allogeneic non-immunosuppressed animals decreased significantly the binding of fluorescence-labelled MHC class I (46.9±19.4%) and class II (65.8±11.9%) antibody to donors spleen cells compared with day 30 sera from both immunosuppressed groups (TAC1, anti-MHC class I 102.4±4.2%, p < 0.001, anti-MHC class II 102.6±6.0%), (TAC7, anti-MHC class I 79.9±3.3%, p < 0.001, anti-MHC class II 80.9±2.7%). CONCLUSION: Both immunosuppressed protocols with tacrolimus (administration from day 1 or from day 7 following transplantation) were able to suppress acute cell- and antibody-mediated rejection of cryopreserved abdominal aortic allografts processed in accordance with our new standardized clinical protocol.
650    _2
$a zvířata $7 D000818
650    _2
$a aorta $x fyziologie $x transplantace $7 D001011
650    12
$a cévní protézy $7 D001807
650    12
$a kryoprezervace $7 D015925
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a rejekce štěpu $x imunologie $7 D006084
650    _2
$a přežívání štěpu $7 D006085
650    _2
$a imunosupresivní léčba $7 D007165
650    _2
$a imunosupresiva $x aplikace a dávkování $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani inbrední BN $7 D011914
650    _2
$a potkani inbrední LEW $7 D011917
650    _2
$a takrolimus $x aplikace a dávkování $7 D016559
650    _2
$a homologní transplantace $7 D014184
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hruby, Jan $u 2nd Department of Surgery - Department of Cardiovascular Surgery, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
700    1_
$a Mericka, Pavel $u Tissue Bank, Faculty Hospital Hradec Kralove, Charles University- Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Mlcek, Mikulas $u Institute of Physiology, First Faculty of Medicine, Charles University in Prague.
700    1_
$a Pecha, Ondrej $u Technology Centre of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Splith, Kathrin $u Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Schmelzle, Moritz $u Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Krenzien, Felix $u Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Lindner, Jaroslav $u 2nd Department of Surgery - Department of Cardiovascular Surgery, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
700    1_
$a Matia, Ivan $u Department of Cardio-Vascular Surgery, Hospital Hietzing and Karl Landsteiner Institute for Cardio-Vascular Research, Vienna, Austria.
700    1_
$a Spacek, Miroslav $u 2nd Department of Surgery - Department of Cardiovascular Surgery, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 13, č. 8 (2018), s. e0201984
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30092051 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190405131420 $b ABA008
999    __
$a ok $b bmc $g 1391796 $s 1050791
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 13 $c 8 $d e0201984 $e 20180809 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options